The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Observing World Hepatitis Day 2015

Back to News Homepage

Next

Safe and Effective Drug for Hepatitis C Genotype 4

New Hepatitis C Treatment Approved By the FDA

July 27, 2015

Print this page

Discover the details behind the FDA’s approval of Daklinza (daclatasvir) for use with sofosbuvir to treat HCV genotype 3 infections.

FDA approves new treatment for chronic hepatitis C genotype 3 infections

The U.S. Food and Drug Administration today approved Daklinza (daclatasvir) for use with sofosbuvir to treat hepatitis C virus (HCV) genotype 3 infections. Daklinza is the first drug that has demonstrated safety and efficacy to treat genotype 3 HCV infections without the need for co-administration of interferon or ribavirin, two FDA-approved drugs also used to treat HCV infection.

Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure. Most people infected with HCV have no symptoms of the disease until liver damage becomes apparent, which may take several years. Some people with chronic HCV infection develop scarring and poor liver function (cirrhosis) over many years, which can lead to complications such as bleeding, jaundice (yellowish eyes or skin), fluid accumulation in the abdomen, infections or liver cancer. According to the Centers for Disease Control and Prevention, approximately 2.7 million Americans are infected with HCV of which, approximately 10 percent are genotype 3.

Continue reading this entire FDA News Release:
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455888.htm

35 Comments
Share
Share

Previous

Observing World Hepatitis Day 2015

Back to News Homepage

Next

Safe and Effective Drug for Hepatitis C Genotype 4

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.